Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
5.36% $46.81
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 3 647.88 mill |
EPS: | -3.69 |
P/E: | -12.69 |
Earnings Date: | May 02, 2024 |
SharesOutstanding: | 77.93 mill |
Avg Daily Volume: | 0.750 mill |
RATING 2024-03-28 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Neutral | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -12.69 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-2.16x |
Company: PE -12.69 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$-5.32 (-111.36%) $-52.13 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 44.28 - 49.35 ( +/- 5.42%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-22 | Knight Jeff E. | Sell | 30 000 | Stock Option (right to buy) |
2024-03-22 | Knight Jeff E. | Buy | 30 000 | Common Stock |
2024-03-22 | Knight Jeff E. | Sell | 30 000 | Common Stock |
2024-03-22 | Knight Jeff E. | Sell | 2 359 | Common Stock |
2024-03-20 | Pizzuti Dana | Sell | 4 375 | Stock Option (right to buy) |
INSIDER POWER |
---|
25.93 |
Last 99 transactions |
Buy: 1 520 833 | Sell: 975 029 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $46.81 (5.36% ) |
Volume | 1.289 mill |
Avg. Vol. | 0.750 mill |
% of Avg. Vol | 171.93 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $38.53 | N/A | Active |
---|
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.